Saturday, July 11, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Clinical program

GSK525762

Phase 1 · small molecule · Solid Tumours

GSK525762 for Solid Tumours is a Phase 1 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

← All GlaxoSmithKline projects Phase 1 small molecule terminated

Internal code 204697

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GlaxoSmithKline
Phase
Phase 1
Modality
small_molecule
Indication
Solid Tumours
Status
terminated
Trials
1

Clinical trials